[Gynecological indications of a new progestational agent with prolonged action].
D000033:Abortion, Threatened / Q000188:drug therapy*; D000230:Adenocarcinoma / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000627:therapeutic use*; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008599:Menstruation Disturbances / Q000188:drug therapy*; D008875:Middle Aged; D011247:Pregnancy; D014384:Tuberculosis, Female Genital / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy
D003692:Delayed-Action Preparations; D008525:Medroxyprogesterone
Indicazioni ginecologiche di un nuovo progestativo ad azione protratta.